1
|
Limonta D, Falcón V, Torres G, Capó V, Menéndez I, Rosario D, Castellanos Y, Alvarez M, Rodríguez-Roche R, de la Rosa MC, Pavón A, López L, González K, Guillén G, Diaz J, Guzmán MG. Dengue virus identification by transmission electron microscopy and molecular methods in fatal dengue hemorrhagic fever. Infection 2012; 40:689-94. [PMID: 22527878 DOI: 10.1007/s15010-012-0260-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2012] [Accepted: 04/02/2012] [Indexed: 01/08/2023]
Abstract
Dengue virus is the most significant virus transmitted by arthropods worldwide and may cause a potentially fatal systemic disease named dengue hemorrhagic fever. In this work, dengue virus serotype 4 was detected in the tissues of one fatal dengue hemorrhagic fever case using electron immunomicroscopy and molecular methods. This is the first report of dengue virus polypeptides findings by electron immunomicroscopy in human samples. In addition, not-previously-documented virus-like particles visualized in spleen, hepatic, brain, and pulmonary tissues from a dengue case are discussed.
Collapse
Affiliation(s)
- D Limonta
- Arbovirus Laboratory, Virology Department, PAHO/WHO Collaborating Center for the Study of Dengue and its Vector, Pedro Kourí Tropical Medicine Institute (IPK), P.O. Box 601, Marianao 13, Havana, Cuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Milá L, Valdés R, Tamayo A, Padilla S, Ferro W. Application of a risk analysis method to different technologies for producing a monoclonal antibody employed in Hepatitis B vaccine manufacturing. Biologicals 2012; 40:118-28. [DOI: 10.1016/j.biologicals.2011.12.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2011] [Revised: 12/08/2011] [Accepted: 12/12/2011] [Indexed: 11/27/2022] Open
|
3
|
Valdés R, Ibarra N, González M, Alvarez T, García J, Llambias R, Pérez CA, Quintero O, Fischer R. CB.Hep-1 hybridoma growth and antibody production using protein-free medium in a hollow fiber bioreactor. Cytotechnology 2011; 35:145-54. [PMID: 19003291 DOI: 10.1023/a:1017921702775] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The protein-free medium TurboDoma HP.1 (THP.1) was used to produce the CB.Hep-1 monoclonal antibody (mAb) in a CP-1000 hollow fiber bioreactor (HFB). This mAb is used for the immunopurification of recombinant hepatitis B surface antigen (rHBsAg), which is included in a vaccine preparation against the Hepatitis B Virus. By using the experimental conditions tested in this work we were able to generate more than 433 mg of IgG in 43 days. The maximum antibody concentration obtained was about 2.4 mg ml(-1)and the IgG production per day was approximately 11 mg of monoclonal antibody, which constitutes a good concentration value in comparison to the results obtained in ascitic fluid, where concentration for this hybridoma was around 3 mg ml(-1). We used different analytical methods to control the quality of mAbs, obtained from the in vitro system. They included affinity constant determination, analysis of N-glycan structures, immunoaffinity chromatography and antigen binding properties. The results obtained suggest that no significant changes occurred in the mean characteristics of the mAb harvested from the bioreactor during the 43 days of cultivation.
Collapse
Affiliation(s)
- R Valdés
- Monoclonal Antibodies Division, Havana University, Cuba,
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Shanmugham R, Thirumeni N, Rao VS, Pitta V, Kasthuri S, Singanallur NB, Lingala R, Mangamoori LN, Villuppanoor SA. Immunocapture enzyme-linked immunosorbent assay for assessment of in vitro potency of recombinant hepatitis B vaccines. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2010; 17:1252-60. [PMID: 20592114 PMCID: PMC2916243 DOI: 10.1128/cvi.00192-10] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2010] [Revised: 06/17/2010] [Accepted: 06/21/2010] [Indexed: 11/20/2022]
Abstract
Quantification of hepatitis B surface antigen (HBsAg) or relative in vitro potency in the final vaccines is a prerequisite for hepatitis B vaccine batch release. The commercial kit for automated analysis (AxSYM) is expensive, and an alternative is required for the estimation of HBsAg in hepatitis B vaccines. Mouse monoclonal antibodies (MAbs) specific for HBsAg were developed and characterized. One of the monoclonal antibodies (HBs06) was used in development of an immunocapture ELISA (IC-ELISA) as an unlabeled capture antibody and biotin-labeled detection antibody. The IC-ELISA was standardized and validated using experimental hepatitis B vaccine batches with various HBsAg concentrations per dose and commercial vaccines. The vaccine was treated with an alkaline solubilizer to desorb the HBsAg from Algel-adjuvanted vaccines before testing, and the sensitivity of the test was 5 ng/ml. A good correlation could be observed between the HBsAg estimates derived by both formats, except for the higher HBsAg concentration range, where the IC-ELISA format could estimate closer to the actual values than AxSYM. There was a significant correlation between the estimated relative potencies of the two methods. There was lack of correlation between the in vivo potency and the relative in vitro potency. However, the estimates of IC-ELISA were comparable to the in vivo values when compared with the estimates of AxSYM. The IC-ELISA can therefore be considered to be a reliable test for deriving in vitro relative potency and antigen concentration in vaccine batches for batch control and release.
Collapse
Affiliation(s)
- Rajalakshmi Shanmugham
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Nagarajan Thirumeni
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Varaprasada Sankarashetty Rao
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Vidyasagar Pitta
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Saranyarevathy Kasthuri
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Nagendrakumar Balasubramanian Singanallur
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Rajendra Lingala
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Lakshmi Narsu Mangamoori
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| | - Srinivasan Alwar Villuppanoor
- Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli, Hyderabad 500032, India, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukkatpally, Hyderabad 500072, India
| |
Collapse
|
5
|
Padilla S, Alvarez T, Ferro W, Guevara Y, Montero J, Gómez L, Gavilán D, Espinosa E, Avila Y, González T, Somoza R, LaO M, Valdés R. Assessment of Synthetic Protein-A MAbsorbents in Antibody Purification from Tobacco Plant Extract. Chromatographia 2010. [DOI: 10.1365/s10337-010-1562-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Cruz LJ, Cabrales A, Iglesias E, Aguilar JC, González LJ, Reyes O. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins. Int Immunopharmacol 2009; 9:1452-9. [DOI: 10.1016/j.intimp.2009.08.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2009] [Revised: 07/26/2009] [Accepted: 08/31/2009] [Indexed: 10/20/2022]
|
7
|
Valdés R, Álvarez T, Tamayo A, Fernandez EG, Montero J, Geada D, Ferro W, Medina Y, Guevara Y, Padilla S, Cecilia D, Dorta L, González M, Sosa R, González T. New Mab CB.Hep-1 Purification Process Eliminates the Need for Pre-Chromatographic Purification. Stability Demonstrated Over 100 Purification Cycles. Chromatographia 2008. [DOI: 10.1365/s10337-008-0607-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Valdés R, Medina Y, Ferro W, Reyes B, Geada D, Montero J, Alvarez T, Leyva A, Gómez L, Padilla S, Pacín L, Figueroa A, Tamayo A, Milá L, Aldama Y, Moya G, Reonde J, Abrahantes MDC. Comparison of different ligand densities in immunoaffinity chromatography of the plantibody HB-01 coupled to Sepharose CL-4B to purify the rHBsAg. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852:1-7. [PMID: 17442634 DOI: 10.1016/j.jchromb.2006.12.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2006] [Revised: 11/23/2006] [Accepted: 12/03/2006] [Indexed: 11/20/2022]
Abstract
This paper evaluates the immunopurification behavior of a plantibody HBsAg specific plantibody coupled to Sepharose CL-4B at different ligand densities. Results show no significant differences in the adsorption and elution capacities, and rHBsAg recovery of immunosorbents at 3.43, 4.45, and 5.31 mg/mL of ligand densities compared to its mouse-derived mAb counterpart consistently used in the rHBsAg purification process. Therefore, plantibody ligand densities higher than 3.43 mg/mL do not improve the immunopurification behavior of this immunosorbent, but increase the antibody consumption and the Hepatitis B vaccine cost. Immunosorbent of 2.23 mg/mL of ligand density demonstrated a poor performance. The IgG leached detectable level never exceeded the approved limit (3 ng IgG/microg rHBsAg). Values close to this limit were only observed at the ligand density of 5.31 and 2.27 mg/mL. In the case of the ligand density of 2.23 mg/mL the IgG leached value was high (2.90 ng IgG/microg rHBsAg) due to a low level of eluted antigen. In conclusion, it supports feasibility of using this plantibody at 3.43 mg/mL of ligand density for large-scale immunopurification of rHBsAg for human use, avoiding the biosafety and ethical concerns of the massive use of animals for this purpose.
Collapse
Affiliation(s)
- Rodolfo Valdés
- Monoclonal Antibody Production Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Hernández R, Plana L, Gómez L, Expósito N, Valdés J, Páez R, Martínez E, Beldarraín A. Optimisation of the coupled monoclonal antibody density for recombinant hepatitis B virus surface antigen immunopurification. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816:1-6. [PMID: 15664326 DOI: 10.1016/j.jchromb.2004.04.020] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2003] [Accepted: 04/15/2004] [Indexed: 10/26/2022]
Abstract
Using immunosorbents based upon cyanogen bromide-Sepharose CL-4B, we have examined different ligand densities in coupling of monoclonal antibody (MAb) to find the best performance, for recombinant hepatitis B surface antigen (rHBsAg) purification. Three replicates of 5 and 15 cycles of densities ranges: 2.17-2.19, 3.18-3.62, 4.06-4.17, and 5.13-5.40 mg/ml (control); or 1.81-2.47, 3.17-3.41, 4.16-4.28, and 5.16-5.19 mg/ml (control), respectively were evaluated in terms of binding capacity, antigen recovery, ligand leakage and purity of antigen, and compared to the control. Adsorption and antigen recovery of immunosorbents manufactured were not different statistically, eventhough increased 8.08 and 9.90% at a range of 3.17-3.41 mg/ml. At this range, efficiency expressed as productivity and MAb saving was optimal. Ligand leakage and purity of antigen showed similar behaviour among all densities. Aspects related to ligand density in antigen immunoaffinity purification are discussed.
Collapse
Affiliation(s)
- Raúl Hernández
- Department of Purification Development Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Ramírez N, Rodríguez M, Ayala M, Cremata J, Pérez M, Martínez A, Linares M, Hevia Y, Páez R, Valdés R, Gavilondo JV, Selman-Housein G. Expression and characterization of an anti-(hepatitis B surface antigen) glycosylated mouse antibody in transgenic tobacco (Nicotiana tabacum) plants and its use in the immunopurification of its target antigen. Biotechnol Appl Biochem 2003; 38:223-30. [PMID: 12797866 DOI: 10.1042/ba20030028] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2003] [Revised: 05/09/2003] [Accepted: 06/10/2003] [Indexed: 11/17/2022]
Abstract
Transgenic plants expressing recombinant immunoglobulins have arisen as an alternative technology for the large-scale production of antibodies useful in therapeutics and in industrial processes. In the present paper we report the expression in transgenic tobacco ( Nicotiana tabacum ) of an anti-HBsAg [anti-(hepatitis B virus surface antigen)] mouse IgG1 mAb (monoclonal antibody), currently used for the industrial purification of the recombinant vaccine antigen. Using the sweet potato sporamin signal peptide, a KDEL (Lys-Asp-Glu-Leu) ER (endoplasmic reticulum) anchorage domain, and a heavy- and light-chain gene tandem construction, we generated F1 plants in which the expression of the antibody accounted for 0.5% of the total soluble proteins. The 'plantibody' (functional IgG antibody produced in plants) was easily purified by Protein A-Sepharose chromatography with a yield of approximately 35 microg/g of fresh leaf material, and its glycosylation indicated that, irrespective of the KDEL signal, the molecule is modified in both the ER and Golgi. Finally, a successful comparison of the plantibody with the ascites-derived mAb in the immunoaffinity purification of the vaccine recombinant HBsAg was performed. Taken as a whole, our results show that the large-scale production of this antibody of industrial relevance in transgenic tobacco is feasible.
Collapse
Affiliation(s)
- Nadia Ramírez
- Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Valdés R, Reyes B, Alvarez T, García J, Montero JA, Figueroa A, Gómez L, Padilla S, Geada D, Abrahantes MC, Dorta L, Fernández D, Mendoza O, Ramirez N, Rodriguez M, Pujol M, Borroto C, Brito J. Hepatitis B surface antigen immunopurification using a plant-derived specific antibody produced in large scale. Biochem Biophys Res Commun 2003; 310:742-7. [PMID: 14550265 DOI: 10.1016/j.bbrc.2003.08.149] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
This paper provides an evaluation of a plant-derived HBsAg-specific antibody in the immunopurification of the recombinant HBsAg for vaccine purposes. This plant-derived antibody was obtained from different batches of 100-200kg of tobacco leaves and coupled to Sepharose CL-4B with high efficiency. The plant-derived antibody immunoaffinity matrix purification behavior (elution capacity, antigen purity, purification cycles, and ligand leakage) was comparable to that of its mouse-derived monoclonal antibody homolog. This result supports the feasibility of using this plant-derived antibody for the immunopurification of the Hepatitis B surface antigen for human use, opening a new possibility to overcome the constrain of monoclonal antibody production in mice.
Collapse
Affiliation(s)
- Rodolfo Valdés
- Monoclonal Antibody Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
González Y, Ibarra N, Gómez H, González M, Dorta L, Padilla S, Valdés R. Expanded bed adsorption processing of mammalian cell culture fluid: comparison with packed bed affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784:183-7. [PMID: 12504196 DOI: 10.1016/s1570-0232(02)00712-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A comparison between expanded bed adsorption and conventional packed bed Protein A Fast Flow to purify the anti-rHBsAg mAbs from feedstock is presented in this work. Direct capture by STREAMLINE expanded bed adsorption chromatography resulted in 92% product recovery and sevenfold more concentrated product with similar purity levels compared to that obtained by the standard packed method. The process time and buffer consumption were reduced in the expanded bed adsorption method not only with the binding-elution conditions but also with the use of NaOH during the cleaning-in-place step. The latter is the most widely accepted agent in downstream processing, being a cost effective technique that provides not only efficient cleaning but also sanitizes complete column systems and destroys pirogens.
Collapse
Affiliation(s)
- Y González
- Monoclonal Antibodies Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, 10600, Havana, Cuba
| | | | | | | | | | | | | |
Collapse
|
13
|
Gómez L, Hernández R, Ibarra N, Valdés R, Campos Y, Tamayo A, Fernández D, Figueroa A, Alvarez T, Montero JA. Comparison of different ligand densities for the manufacture of CB Hep-1 immunosorbents. JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS 2002; 52:151-9. [PMID: 12376018 DOI: 10.1016/s0165-022x(02)00013-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Different ligand densities of monoclonal antibody (Mab) CB.Hep-1 were studied during covalent coupling on Sepharose CL-4B for recombinant hepatitis B surface antigen (rHBsAg) immunoaffinity purification. Ligand densities of 2.2, 3.2, 4.2 and 5.2 mg Mab/ml immunosorbents, respectively, were assayed during five cycles of immunoaffinity chromatography (IAC). Adsorption capacities averaged either 3.2 mg/ml (0.57 mg rHBsAg/ml immunosorbent/5.42 mg of total purified protein) or 5.2 mg/ml (0.56 mg rHBsAg/ml immunosorbent/5.05 mg total purified protein). Immunosorbents showed ligand leakage levels below 3 ng Mab/microg rHBsAg. Antigen purity was higher than 95% in all cases. The results suggest that a ligand density (LD) of 3.2 mg Mab/ml immunosorbent should be used for immunoaffinity chromatography because no significant differences were found in the ligand densities studied (P-value=0.012), which saves 40% of CB.Hep-1 immunosorbent manufacturing cost in comparison with 5 mg Mab/ml immunosorbent, which is currently used in large-scale production.
Collapse
Affiliation(s)
- L Gómez
- Monoclonal Antibodies Department, Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, P O Box 6162, Havana 10600, Cuba.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Valdés R, Ibarra N, Ruibal I, Beldarraín A, Noa E, Herrera N, Alemán R, Padilla S, Garcia J, Pérez M, Morales R, Chong E, Reyes B, Quiñones Y, Agraz A, Herrera L. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses. J Biotechnol 2002; 96:251-8. [PMID: 12044553 PMCID: PMC7126170 DOI: 10.1016/s0168-1656(02)00047-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
The virus removal of protein A affinity chromatography, inactivation capacity, acid pH and a combination of high temperature with a chaotropic agent was determined in this work. The model viruses studied were sendaivirus, human immunodeficency virus (HIV-IIIb), human poliovirus type-II, human herpesvirus I and canine parvovirus. The protein A affinity chromatography showed a maximum reduction factor of 8 logs in the case of viruses larger than 120 nm size, while for small viruses (18-30 nm) the maximum reduction factor was about 5 logs. Non viral inactivation was observed during the monoclonal antibody elution step. Low pH treatment showed a maximum inactivation factor of 7.1 logs for enveloped viruses. However, a weak inactivation factor (3.4 logs) was obtained for DNA nonenveloped viruses. The combination of high temperature with 3 M KSCN showed a high inactivation factor for all of the viruses studied. The total clearance factor was 23.1, 15.1, 13.6, 20.0 and 16.0 logs for sendaivirus, HIV-IIIb, human poliovirus type-II, human herpesvirus I and canine parvovirus, respectively.
Collapse
Affiliation(s)
- R Valdés
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - Neysi Ibarra
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
- Corresponding author. Tel.: +53-7-271-6022; fax: +53-7-271-3208
| | - I Ruibal
- National Reference Center for AIDS, PO Box 23031, Havana, Cuba
| | - A Beldarraín
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - E Noa
- National Reference Center for AIDS, PO Box 23031, Havana, Cuba
| | - N Herrera
- National Reference Center for AIDS, PO Box 23031, Havana, Cuba
| | - R Alemán
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - S Padilla
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - J Garcia
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - M Pérez
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - R Morales
- National Center for Bioreagents, PO Box 6048, Havana, Cuba
| | - E Chong
- National Center for Bioreagents, PO Box 6048, Havana, Cuba
| | - B Reyes
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - Y Quiñones
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - A Agraz
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| | - L Herrera
- Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba
| |
Collapse
|
15
|
Hernández R, Chong E, Morales R, Pérez E, Amador Y, Zubiaurrez JR, Valdés R, Figueroa A, Agraz A, Herrera L. Stirrer tank: an appropriate technology to immobilize the CB.Hep-1 monoclonal antibody for immunoaffinity purification. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2001; 754:77-83. [PMID: 11318429 DOI: 10.1016/s0378-4347(00)00590-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The CB.Hep-1 monoclonal antibody was coupled to CNBr-activated Sepharose CL 4B at three different immobilization scales for purification of recombinant hepatitis B surface antigen. Standard laboratory apparatus to obtain immunosorbents of 1 l (scale I) and 3 l (scale II) as well as a stirrer tank to prepare 6 l immunosorbents (scale III) were used. The binding capacity at scale III was 2- and 1.5-fold higher with respect to the scales II and I, while a reduction in the ligand leakage of 5- and 2-folds was observed. Immunosorbents from scale II showed a significantly reduced adsorption, and an increased ligand leakage. Differences in the coupling efficiency were not observed. Antigen purity eluted from the immunosorbents was always above 85%.
Collapse
Affiliation(s)
- R Hernández
- Monoclonal Antibody Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
| | | | | | | | | | | | | | | | | | | |
Collapse
|